Since GFP is a trackable marker, tumor-residing GFP+/CD11b+/Lyve-1+ cells that lacked T-cell and erythroid markers were clearly derived from an initially positive subset generated in vitro rather than from unknown precursors. The gene discussed is LYVE1; the disease is neoplasm.